Risslegger, BZoran, TLackner, MAigner, MSánchez-Reus, FRezusta, AChowdhary, ATaj-Aldeen, S JArendrup, M COliveri, SKontoyiannis, D PAlastruey-Izquierdo, ALagrou, KLo Cascio, GMeis, J FBuzina, WFarina, CDrogari-Apiranthitou, MGrancini, ATortorano, A MWillinger, BHamprecht, AJohnson, EKlingspor, LArsic-Arsenijevic, VCornely, O AMeletiadis, JPrammer, WTullio, VVehreschild, J-JTrovato, LLewis, R ESegal, ERath, P-MHamal, PRodriguez-Iglesias, MRoilides, EArikan-Akdagli, SChakrabarti, AColombo, A LFernández, M SMartin-Gomez, M TBadali, HPetrikkos, GKlimko, NHeimann, S MHoubraken, JUzun, OEdlinger, MFuente, S de laLass-Flörl, C2023-01-252023-01-252017-04-13http://hdl.handle.net/10668/11097A prospective international multicentre surveillance study was conducted to investigate the prevalence and amphotericin B susceptibility of Aspergillus terreus species complex infections. A total of 370 cases from 21 countries were evaluated. The overall prevalence of A. terreus species complex among the investigated patients with mould-positive cultures was 5.2% (370/7116). Amphotericin B MICs ranged from 0.125 to 32 mg/L, (median 8 mg/L). Aspergillus terreus species complex infections cause a wide spectrum of aspergillosis and the majority of cryptic species display high amphotericin B MICs.enAmphotericin BAspergillosisAspergillus terreusCrytic speciesIn vitrosusceptibilityAmphotericin BAntifungal AgentsAspergillosisAspergillusEpidemiological MonitoringEuropeHumansMicrobial Sensitivity TestsPrevalenceProspective Studiesresearch article28412383open access10.1016/j.cmi.2017.04.0121469-0691http://www.clinicalmicrobiologyandinfection.com/article/S1198743X17302203/pdf